# Pfizer and Blackstone Secure $1.5 Billion for Obesity Drug

> Pfizer and Blackstone Life Sciences agree to fund berobenatide's development up to $1.5 billion by 2028.
- Title: Pfizer and Blackstone Secure $1.5 Billion for Obesity Drug
- Summary: Pfizer and Blackstone Life Sciences agree to fund berobenatide's development up to $1.5 billion by 2028.
- Keywords: pfizer, blackstone life sciences, berobenatide, glp-1, obesity drug, clinical trials, cardiometabolic pipeline, milestone payments, regulatory approval, sales targets, Pulse 2.0
- Source: Pulse 2.0 — https://pulse2.com/pfizer-up-to-1-5-billion-funding-agreement-with-blackstone-life-sciences-to-advance-monthly-glp-1-obesity-drug
- Author: Amit Chowdhry
- Published: 2026-11-13T19:21:30+00:00
- Read time: 1 min
- Topics: pfizer, blackstone life sciences, berobenatide, glp-1, obesity drug, clinical trials, cardiometabolic pipeline, milestone payments, regulatory approval, sales targets, startups, business
## Funding Agreement Details
Pfizer and Blackstone Life Sciences entered a strategic funding agreement for up to $1.5 billion through 2028 to support berobenatide's clinical development.
## Funding Structure
Blackstone will receive milestone payments tied to U.S. regulatory approval and commercial sales targets for berobenatide.
## Berobenatide Overview
Berobenatide is an investigational monthly GLP-1 receptor agonist peptide for chronic weight management and obesity-related conditions.
## Clinical Development Plan
Pfizer plans over 20 clinical trials in 2026, including 10 Phase 3 trials for berobenatide's safety and effectiveness.
## Cardiometabolic Focus
Pfizer positions berobenatide as a key treatment for knee osteoarthritis and obstructive sleep apnea alongside weight management.
## Blackstone's Role
Blackstone Life Sciences provides $18 billion in assets to support pharmaceutical research through milestone-based investments.
## Milestone Payments
Blackstone earns payments if berobenatide gets U.S. regulatory approval and meets sales targets for chronic weight management.
## Ownership and Control
Pfizer retains full control over berobenatide's clinical development and decision-making without selling ownership.
## Next Steps
Pfizer aims to accelerate cardiometabolic research while maintaining financial flexibility through 2028.
## Key takeaway

Pfizer secured $1.5 billion in funding from Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through 2028.